Vasculitis: Risks and rewards of treating elderly patients with vasculitis

Nature Reviews Nephrology

Volumn 7, Issue 5, 2011, Pages 253-255

  Tarzi, Ruth M ^a   Pusey, Charles D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

AGED; ANCA ASSOCIATED VASCULITIS; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; GERIATRIC PATIENT; GLOMERULONEPHRITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; REMISSION; RISK BENEFIT ANALYSIS; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; AGING; HUMANS; IMMUNOSUPPRESSION; RISK FACTORS; VASCULITIS;

EID: 79955613228     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.30     Document Type: Short Survey

References (10)

1. Moutzouris, D. A. et al. Renal biopsy in the very elderly. Clin. J. Am. Soc. Nephrol. 4, 1073-1082 (2009).
2. Harper, L. & Savage, C. O. ANCA-associated renal vasculitis at the end of the twentieth century-a disease of older patients. Rheumatology (Oxford) 44, 495-501 (2005). (Pubitemid 41511141)
3. Chen, M., Yu, F., Zhang, Y. & Zhao, M. H. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 87, 203-209 (2008).
4. Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036-1043 (2010).
5. Flossman, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488-494 (2011).
6. Mukhtyar, C. & Luqmani, R. Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. Clin. Exp. Rheumatol. 25 (Suppl. 47), 120-129 (2007).
7. Bomback, A. S. et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. doi:10.1038/ki.2010.489.
8. de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670-680 (2009).
9. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
10. Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211-220 (2010).